118th Congress · HOUSE BILLBILL

H.R. 1825 — Right to Try Clarification Act

“To clarify that the Federal Right to Try law applies to schedule I substances for which a phase I clinical trial has been completed and to provide access for eligible patients to such substances pursuant to the Federal Right to Try law.”

Health

Introduced Mar 28, 2023

Last action Apr 7, 2023

Pipeline · Bill → Law

Step 1

Introduced

Mar 28, 2023

Step 2

Referred

Apr 7, 2023

E&C · Judiciary

Step 3

Committee

Step 4

House floor

Step 5

Senate

Step 6

Resolve Changes

Step 7

Signed

SummaryCRS Summary

This bill specifies that investigational drugs that are provided via the Right to Try pathway are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances). The Right to Try pathway allows drug manufacturers to provide certain investigational drugs for which a Phase I clinical trial has been completed, but that have not yet received approval from the Food and Drug Administration, directly to individuals who have imminently life-threatening diseases or conditions and who have exhausted other treatment options and are unable to participate in clinical trials.

Provisions · 3 sectionsIntroduced in House

Timeline · 5 actions

Apr 7, 2023

Referred to the Subcommittee on Health.

Mar 28, 2023

Introduced in House

Mar 28, 2023

Sponsor introductory remarks on measure.

Mar 28, 2023

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Mar 28, 2023